TSX:CRONPharmaceuticals
Cronos Group (TSX:CRON) Following Profit Return, Is The Fair Value Case Still Intact?
Cronos Group (TSX:CRON) has drawn fresh attention after reporting second quarter 2026 results that show higher sales, a move to net income and positive earnings per share from continuing operations.
See our latest analysis for Cronos Group.
The latest earnings swing to profit and ongoing share buybacks appear to be feeding into sentiment, with Cronos Group posting a 13.52% 1 month share price return and a 29.36% 1 year total shareholder return. The 5 year total shareholder return remains down...